Xi’An International Medical Investment Company Limited(000516) (000516)
The epidemic situation in China is generally stable, and the normalization of epidemic prevention and control in Xi’an is progressing steadily
On December 20, 2021, at the press conference held by the joint prevention and control mechanism of the State Council, Lei Zhenglong, deputy director of the disease control bureau of the National Health Commission and first-class inspector, pointed out that the epidemic situation in the country was generally stable. The related epidemic situation in Manzhouli, Inner Mongolia has been basically controlled. The epidemic situation in Shaoxing, Zhejiang Province has slowed down and the risk of epidemic spillover has been reduced. Xi’an Dongguan related epidemic has a high risk of continuous transmission. Sporadic spillover cases have been found recently, and the investigation of risk personnel is being carried out quickly. On the whole, the epidemic prevention and control work has been normalized, and the sporadic epidemic can be effectively controlled within a certain period of time.
Nucleic acid detection of all staff has been started in many places in Xi’an. After the risk is eliminated, the outpatient and emergency departments of many hospitals are expected to recover
At present, the prevention and control work in Xi’an continues to advance, and a new round of full staff nucleic acid detection will begin on December 21, 2021. In response to the needs of epidemic prevention and control, outpatient and emergency treatment of the Second Affiliated Hospital of Jiaotong University and aerospace general hospital were suspended, and the outpatient service of the First Affiliated Hospital of Jiaotong University was suspended for 3 days. Shaanxi Provincial People’s hospital carried out comprehensive killing in the outpatient and emergency areas. On December 15, except for fever and children’s clinics, other outpatient visits resumed. At present, consultation and suspension are mainly routine operations of epidemic prevention risk control management and internal killing. It is expected that each hospital will resume reception after the risk is eliminated.
The second half of the year ushered in the peak of medical treatment, and the business trend of the company accelerated and the upward trend remained unchanged
In 2021, all high-tech hospitals, central hospitals and new hospital areas of Shangluo Hospital of Q3 company were put into operation, and the overall scale of medical service business continued to expand. Since the third quarter of 2021, the daily inpatient beds of Xi’An International Medical Investment Company Limited(000516) central hospital have successively reached a record high, with a maximum of 2300 beds, the maximum number of daily inpatient beds of high-tech hospital has exceeded 1400, and the number of daily inpatient beds of Xi’an Xi’An International Medical Investment Company Limited(000516) Shangluo hospital has also increased significantly compared with the previous period. With the arrival of the peak of medical treatment in the second half of the year, the revenue increased month on month. In 2021, q1-q3 revenue was 632 million yuan, 674 million yuan and 742 million yuan respectively. In 2021, Q2 and Q3 grew by 6.62% and 10.11% month on month respectively. The increase in the number of visits led to the release of performance, and it is expected to further increase in the fourth quarter.
Miao you’s cooperation has been implemented, and its core competitiveness has been continuously enhanced
On December 8, 2021, Xi’An International Medical Investment Company Limited(000516) Central Hospital and Xi’an high tech hospital officially signed a cooperation agreement with the world-famous medical institution mayoclinic, becoming a member Hospital of miaoyou medical alliance, marking Xi’An International Medical Investment Company Limited(000516) The medical quality and hospital management level of the center and high-tech hospital have been in line with the world-class medical service system. The company’s hospitals are constantly improving in terms of discipline talent expansion, research platform system and brand service construction, which has laid the cornerstone of rapid development in the future.
Profit forecast
As the number of visits in its hospitals continues to climb and the performance scale continues to increase, the company is expected to become a dark horse in the field of medical services. It is estimated that the company’s operating revenue from 2021 to 2023 will be RMB 3.065/5.048/6.9 billion respectively; The net profit attributable to the parent company is -278 / 318 / 542 million yuan respectively (excluding the income from changes in fair value); EPS is -0.12 yuan, 0.14 yuan and 0.24 yuan respectively. Xi’An International Medical Investment Company Limited(000516) has long-term advantages and potential in talent echelon, business scale and business model, and maintains the “buy” rating.
Risk warning: the climbing speed of the bed is lower than expected; The capital expenditure in the early stage of hospital operation is large
